Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

著者: Peter Schmid, Roberto Salgado, Y.H. Park, Eva Muñoz‐Couselo, S.B. Kim, Joohyuk Sohn, Seock‐Ah Im, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, L. Yin, A. Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés, Sherene Loi - Annals of Oncology 2020 被引用: 435